Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bart De Corte is active.

Publication


Featured researches published by Bart De Corte.


Antimicrobial Agents and Chemotherapy | 2004

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries; Hilde Azijn; Theo Thielemans; Donald William Ludovici; Michael Joseph Kukla; Jan Heeres; Paul A. J. Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune

ABSTRACT Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1); however, currently marketed NNRTIs rapidly select resistant virus, and cross-resistance within the class is extensive. A parallel screening strategy was applied to test candidates from a series of diarylpyrimidines against wild-type and resistant HIV strains carrying clinically relevant mutations. Serum protein binding and metabolic stability were addressed early in the selection process. The emerging clinical candidate, TMC125, was highly active against wild-type HIV-1 (50% effective concentration [EC50] = 1.4 to 4.8 nM) and showed some activity against HIV-2 (EC50 = 3.5 μM). TMC125 also inhibited a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. Incubation of TMC125 with human liver microsomal fractions suggested good metabolic stability (15% decrease in drug concentration and 7% decrease in antiviral activity after 120 min). Although TMC125 is highly protein bound, its antiviral effect was not reduced by the presence of 45 mg of human serum albumin/ml, 1 mg of α1-acid glycoprotein/ml, or 50% human serum. In an initial screen for activity against a panel of 25 viruses carrying single and double reverse transcriptase amino acid substitutions associated with NNRTI resistance, the EC50 of TMC125 was <5 nM for 19 viruses, including the double mutants K101E+K103N and K103N+Y181C. TMC125 also retained activity (EC50 < 100 nM) against 97% of 1,081 recent clinically derived recombinant viruses resistant to at least one of the currently marketed NNRTIs. TMC125 is a potent next generation NNRTI, with the potential for use in individuals infected with NNRTI-resistant virus.


Bioorganic & Medicinal Chemistry Letters | 2001

Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues

Donald William Ludovici; Bart De Corte; Michael Joseph Kukla; Hong Ye; Chih Y. Ho; Mark A. Lichtenstein; Robert W. Kavash; Koen Andries; Marie-Pierre de Béthune; Hilde Azijn; Rudi Pauwels; Paul J. Lewi; Jan Heeres; Lucien Maria Henricus Koymans; Marc René De Jonge; Koen Jeanne Alfons Van Aken; Frederik Frans Desire Daeyaert; Kalyan Das; Edward Arnold; Paul A. J. Janssen

The synthesis and anti-HIV-1 activity of a series of diarylpyrimidines (DAPYs) are described. Several members of this novel class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) are extremely potent against both wild-type and a panel of clinically significant single- and double-mutant strains of HIV-1.


Bioorganic & Medicinal Chemistry Letters | 2001

Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues.

Donald William Ludovici; Robert W. Kavash; Michael Joseph Kukla; Chih Y. Ho; Hong Ye; Bart De Corte; Koen Andries; Marie-Pierre de Béthune; Hilde Azijn; Rudi Pauwels; Henry E.L. Moereels; Jan Heeres; Lucien Maria Henricus Koymans; Marc René De Jonge; Koen Jeanne Alfons Van Aken; Frederik Frans Desire Daeyaert; Paul J. Lewi; Kalyan Das; Edward Arnold; Paul A. J. Janssen

A synthesis program directed toward improving the stability of imidoyl thiourea based non-nucleoside reverse transcriptase inhibitors (NNRTIs) led to the discovery of diaryltriazines (DATAs), a new class of potent NNRTIs. The synthesis and anti-HIV structure-activity relationship (SAR) studies of a series of DATA derivatives are described.


Journal of Computer-aided Molecular Design | 2003

On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data

Paul J. Lewis; Marc René De Jonge; Frits Daeyaert; Luc Koymans; Maarten Vinkers; Jan Heeres; Paul A. J. Janssen; Eddy Arnold; Kalyan Das; D Art ClarkJr.; Stephen H. Hughes; Paul L. Boyer; Marie-Pierre de Béthune; Rudi Pauwels; Koen Andries; Mike Kukla; Donald William Ludovici; Bart De Corte; Robert W. Kavash; Chih Ho

There are several indications that a given compound or a set of related compounds can bind in different modes to a specific binding site of a protein. This is especially evident from X-ray crystallographic structures of ligand-protein complexes. The availability of multiple binding modes of a ligand in a binding site may present an advantage in drug design when simultaneously optimizing several criteria. In the case of the design of anti-HIV compounds we observed that the more active compounds that are also resilient against mutation of the non-nucleoside binding site of HIV1-reverse transcriptase make use of more binding modes than the less active and resilient compounds.


Heterocycles | 2004

A concise synthesis of an indenopyrrolidine-based dual αvβ3/αvβ5 integrin antagonist

Diane K. Luci; Rosemary J. Santulli; Diane A. Gauthier; Brett A. Tounge; Shyamali Ghosh; Jef C. Proost; William A. Kinney; Bart De Corte; Robert A. Galemmo; Joan M. Lewis; Warren E. Dorsch; Michael W. Wagaman; Bruce P. Damiano; Bruce E. Maryanoff

A new class of dual α v β 3 /α v β 5 integrin antagonists containing a central cis-fused cyclopentane ring was identified. Because of its increased structural rigidity, the indenopyrrolidine ring system provides insight intothe active conformation of other α v β 3 ligands. A concise synthesis of the indenopyrrolidine ring system was accomplished by 1,3-dipolar cycloaddition. Individual isomers of the most active compound were separated by chiral HPLC and their biological activities were compared.


Journal of Medicinal Chemistry | 2004

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants

Kalyan Das; Arthur D. Clark; Paul J. Lewi; Jan Heeres; Marc René De Jonge; Lucien Maria Henricus Koymans; H. Maarten Vinkers; Frederik Frans Desire Daeyaert; Donald William Ludovici; Michael Joseph Kukla; Bart De Corte; Robert W. Kavash; Chih Y. Ho; Hong Ye; Mark A. Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre de Béthune; Paul L. Boyer; Patrick K. Clark; Stephen H. Hughes; Paul A. J. Janssen; Eddy Arnold


Archive | 1999

Hiv replication inhibiting pyrimidines

Bart De Corte; Marc René De Jonge; Jan Heeres; Chih Yung Ho; Paul A. J. Janssen; Robert W. Kavash; Lucien Maria Henricus Koymans; Michael Joseph Kukla; Donald William Ludovici; Koen Jeanne Alfons Van Aken


Archive | 2001

HIV replication inhibitors

Michael Joseph Kukla; Donald William Ludovici; Robert W. Kavash; Bart De Corte; Jan Heeres; Paul A. J. Janssen; Lucien Maria Henricus Koymans; Marc René De Jonge; Koen Jeanne Alfons Van Aken; Alain Krief; Ruben Gerardus George Leenders


Archive | 1999

HIV inhibiting pyrimidine derivative

Koenraad Jozef Lodewijk Marcel Andries; Bart De Corte; Marc René De Jonge; Jan Heeres; Chih Yung Ho; Marcel Janssen; Paul A. J. Janssen; Lucien Maria Henricus Koymans; Michael Joseph Kukla; Donald William Ludovici; Koen Jeanne Alfons Van Aken


Archive | 2001

Prodrugs of hiv replication inhibiting pyrimidines

Michael Joseph Kukla; Donald William Ludovici; Robert W. Kavash; Bart De Corte; Jan Heeres; Paul A. J. Janssen; Lucien Maria Henricus Koymans; Marc René De Jonge; Koen Jeanne Alfons Van Aken; Alain Krief

Collaboration


Dive into the Bart De Corte's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge